Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Ipilimumab + Nivolumab & Non-small-cell lung cancer (NSCLC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Regulatory status

Concerning Ipilimumab + Nivolumab & Non-Small-Cell-Lung-Cancer (NSCLC), Ipilimumab + Nivolumab is approved by both FDA and EMA for certain first-line indications in metastatic Non-Small-Cell-Lung-Cancer (NSCLC), with defined molecular and sometimes PD‑L1 criteria. FDA has approved nivolumab + ipilimumab as first‑line treatment for metastatic NSCLC in patients with PD‑L1 ≥1% and without EGFR or ALK genomic aberrations, based on CheckMate 227 (1).

Clinical data

First-line [Ipilimumab + Nivolumab](brain://Je7JJ8K8JEKPyl66ML6oYA/…

References (Sources)

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase III trial
Paz-Ares et al. 2021 The Lancet Oncology 22: 198-211
First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, openlabel, phase 3 CheckMate 227 part 1 trial
Paz-Ares et al. 2022 J Thorac Oncol 17: 289-308
Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in ﬁrst-line metastatic lung cancer
Halmos et al. 2022 Immunotherapy 14(5) 295-307
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Reuss et al. 2020
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Hellmann et al. 2019 N Engl J Med 381: 2020-2031
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Hellmann et al. 2018 NEJM 378: 2093-2104
Nivolumab plus ipilimumab in non-small-cell lung cancer
Reck et al. 2019a
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: